Vidac Pharma's Positive Phase 2b Trial Results

Vidac Pharma Holding Plc recently announced encouraging results from a Phase 2b trial of its drug candidate, VDA-1102. This trial focused on patients with rapidly proliferating actinic keratosis (AK). The study was randomized, double-blind, and placebo-controlled, indicating robust research methods.

Significant findings include a notable decrease in the proportion of patients with severe Grade III lesions. In the VDA-1102 group, this decreased from 76.9% to 37.5%, contrasting with a minor reduction in the placebo group. While these results are promising, the small patient sample and variability in disease severity may affect statistical interpretations.

Sphene Capital GmbH has maintained a "Buy" recommendation for Vidac Pharma, adjusting the target price to EUR 3.80, reflecting both development prospects and inherent risks.